PRESSURE ULCERS TREATMENT MARKET ANALYSIS

Pressure ulcers (pressure sores and/or bedsores) are injuries to the skin and underlying tissue, mostly caused by prolonged pressure on the skin. They can happen to anyone, but commonly affect individuals confined to a bed or sitting in a chair or wheelchair for long periods of time. Pressure ulcers treatment include using special mattresses to reduce/relieve pressure, regularly changing a position, and dressings to help heal the ulcer. Sometimes, surgery may be needed. It is recommended to clean open sores with water or saline (saltwater) every time the dressing is changed. Moreover, a bandage speeds healing by keeping the wound moist. It also creates a barrier against infection and keeps the skin around it dry. Most sores heal with pressure ulcers treatment, but some never heal completely.

Market Statistics:

The global pressure ulcers treatment market was valued at US$ 4,653.0 Mn in 2021 and is forecast to reach a value of US$ 7,108.0 Mn by 2028 at a CAGR of 6.2% between 2022 and 2028.

North America held dominant position in the global pressure ulcers treatment market in 2020, accounting for 39.4% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Pressure Ulcers Treatment Market Share (%), by Region, 2021

To learn more about this report, request a free sample copy

Recent Developments:

In September 2020, Integra LifeSciences Holdings Corp. entered into a definitive agreement to sell its Extremity Orthopedics business to Smith+Nephew.

In March 2020, Smith+Nephew launched the PICO 14 Single Use Negative Pressure Wound Therapy System for use on high-risk surgical patients.

In February 2020, Integra LifeSciences Holding Corporation launched the AmnioExcel Plus Placental Allograft Membrane, its latest wound care offering to support soft tissue repair.

Market Drivers:

1. Increasing incidence of pressure ulcer is expected to augment growth of the global pressure ulcers treatment market during the forecast period. For instance, according to the Agency for Healthcare Research and Quality (the U.S. Department of Health and Human Services), each year, over 2.5 million people in the United States develop pressure ulcers. The aim of pressure ulcers treatment is to assist hospital staff in implementing effective pressure ulcer prevention practices through an interdisciplinary approach to care.
2. Rising geriatric population across the globe is expected to boost growth of the global pressure ulcers treatment market over the forecast period. For instance, the geriatric population is more prone to the development of pressure ulcers that are also known as bedsores. According to the World Health Organization (WHO), the number and proportion of people aged 60 years and older in the population is increasing. In 2019, the number of people aged 60 years and older was 1 billion, and is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050.

Figure 2. Global Pressure Ulcers Treatment Market Share (%), by Product Type, 2021

To learn more about this report, request a free sample copy

Market Restraints:

1. High cost of advanced wound care products is expected to hamper the growth of the global pressure ulcers treatment market. For instance, according to the U.S. Department of Health and Human Services, pressure ulcers cost US$ 9.1-11.6 billion per year in the United States. Cost of patient care ranges from US$ 20,900 to 151,700 per pressure ulcer. People (especially those who live in villages) cannot even afford the cheapest treatment. These alarming expenses are contributing to the rising demand for bedsore management equipment.
2. Lack of awareness about pressure ulcers is expected to hinder growth of the global pressure ulcers treatment market. For instance, the development of pressure ulcers can interfere with the patient's functional recovery, may be complicated by pain and infection, and can contribute to longer hospital stays. Since these ulcers can be prevented with proper treatment/management, there is a need for awareness campaigns to raise awareness.

Market Opportunities:

1. Increasing demand for faster recovery of wounds is expected to provide significant growth opportunities for players in the global pressure ulcers treatment market. For instance, in March 2021, Smith+Nephew announce the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped to significantly reduce dressing change frequency and weekly dressing costs, while improving treatment satisfaction for clinicians and patients in a community setting.
2. Increase in awareness among people or favorable government initiatives is expected to offer lucrative growth opportunities for players in the global pressure ulcers treatment market. For instance, as these ulcers can be prevented with proper management, many campaigns have been launched to raise public awareness. Zero Pressure, Stop the Pressure, and Islandwide Pressure Ulcer Prevention Campaign are some of the campaigns initiated by the U.K. government.

Market Trends/Key Takeaways:

1. Increasing prevalence of chronic diseases worldwide is expected to people the growth of the global pressure ulcers treatment market. Diabetes increases the risk of pressure ulcers because of its association with nerve damage (neuropathy) and poor circulation. Thus, with the increase in prevalence of diabetes, the incidence of pressure ulcers is also increasing. According to the National Center for Biotechnology Information, the prevalence of diabetes (type 1 and 2) will increase by 54% to more than 54.9 million Americans between 2015 and 2030.
2. Increasing demand for safe and effective treatment is expected to drive growth of the global pressure ulcers treatment market. For instance, in February 2021, Axis Biosolutions received European CE mark approval for the advanced wound care product, MAxiCel, which is used in several chronic wounds, including pressure ulcers.​

Competitive Landscape:

1. Smith & Nephew PLC
2. Integra Lifesciences Holdings Corporation
3. Hill-Rom Holdings Inc.
4. Molnlycke Health Care AB
5. Cardinal Health Inc.
6. Essity Aktiebolag
7. 3M Company
8. Braun Melsungen AG
9. ConvaTec Group PLC
10. Coloplast Group